Osteoblast
A bone-forming cell responsible for producing and mineralising new bone matrix. PTH analogues (teriparatide, abaloparatide) work by stimulating osteoblast activity when given in intermittent pulses. Osteoblast stimulation is the unique anabolic mechanism that distinguishes PTH-based therapies from anti-resorptive treatments.
Technical Context
Osteoblasts differentiate from mesenchymal stem cells through a pathway regulated by Runx2 (master transcription factor for osteoblast commitment), Osterix, and Wnt/β-catenin signalling. Mature osteoblasts synthesise and secrete type I collagen (forming the organic bone matrix/osteoid), alkaline phosphatase (involved in mineralisation), and osteocalcin (a bone-specific protein). Approximately 60-80% of osteoblasts die by apoptosis after completing matrix deposition; the remainder become osteocytes (embedded in mineralised matrix, sensing mechanical load) or bone lining cells (quiescent surface cells). PTH analogue mechanism: intermittent PTH(1-34) exposure (daily injection producing a brief pulse) activates PTH1R on osteoblasts → Gαs/cAMP/PKA and Wnt/β-catenin signalling → increased osteoblast number (promoting differentiation, inhibiting apoptosis) → increased bone formation rate. This anabolic window (osteoblast stimulation exceeding osteoclast stimulation) lasts for approximately 18-24 months of treatment.